TSHA
Taysha Gene Therapies Inc
NASDAQ: TSHA · HEALTHCARE · BIOTECHNOLOGY
$6.39
+1.91% today
Updated 2026-04-30
Market cap
$1.80B
P/E ratio
—
P/S ratio
184.35x
EPS (TTM)
$-0.34
Dividend yield
—
52W range
$2 – $7
Volume
2.8M
Taysha Gene Therapies Inc (TSHA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-516.00%
ROE
-68.40%
ROA
-27.40%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | — | $-1.11M | — | — | — |
| 2020 | $0.00 | $-43.00M | — | — | — |
| 2021 | $0.00 | $-174.52M | — | — | — |
| 2022 | $2.50M | $-166.01M | 0.60% | -5,037.05% | -6,635.25% |
| 2023 | $15.45M | $-111.57M | 100.00% | -468.83% | -722.06% |
| 2024 | $8.33M | $-89.30M | 100.00% | -1,097.55% | -1,071.62% |
| 2025 | $9.77M | $-109.00M | 88.28% | -1,130.65% | -1,115.27% |